Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab vs Standard Treatment for Checkpoint Inhibitor Induced Colitis
NCT04797325Phase 2Unknown
- Sponsor
- University of Copenhagen
- Start
- Aug 2021
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vedolizumab in immune-mediated colitis, sponsored by University of Copenhagen. Primary endpoint: dose of prednisolone at 30 weeks. Status: unknown.
02
Drugs
vedolizumab
03
Conditions
immune-mediated colitis
Beyond the preview
Go deeper on NCT04797325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797325.